FibroBiologics (NASDAQ:FBLG) Insider Acquires $11,400.00 in Stock

FibroBiologics Inc. (NASDAQ:FBLG) insider Hamid Khoja acquired 30,000 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was acquired at an average cost of $0.38 per share, with a total value of $11,400.00. Following the completion of the purchase, the insider directly owned 61,250 shares in the company, valued at approximately $23,275. This represents a 96.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

FibroBiologics Trading Up 3.8%

Shares of NASDAQ FBLG opened at $0.44 on Friday. FibroBiologics Inc. has a 12-month low of $0.22 and a 12-month high of $1.53. The firm’s 50-day moving average price is $0.30 and its 200-day moving average price is $0.38. The stock has a market capitalization of $29.41 million, a price-to-earnings ratio of -1.04 and a beta of -0.69.

FibroBiologics (NASDAQ:FBLG) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.06. On average, equities analysts predict that FibroBiologics Inc. will post -0.53 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of FibroBiologics in a research report on Thursday, January 22nd. D. Boral Capital lowered their target price on shares of FibroBiologics from $15.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. Finally, HC Wainwright cut their price target on shares of FibroBiologics to $4.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, FibroBiologics presently has an average rating of “Hold” and a consensus target price of $5.50.

Institutional Trading of FibroBiologics

A number of large investors have recently modified their holdings of FBLG. AQR Capital Management LLC purchased a new position in FibroBiologics during the 1st quarter worth $29,000. XTX Topco Ltd lifted its holdings in shares of FibroBiologics by 160.0% in the 2nd quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock worth $29,000 after buying an additional 28,276 shares during the period. Ethos Financial Group LLC lifted its holdings in shares of FibroBiologics by 100.0% in the 2nd quarter. Ethos Financial Group LLC now owns 48,848 shares of the company’s stock worth $30,000 after buying an additional 24,424 shares during the period. Y Intercept Hong Kong Ltd bought a new position in shares of FibroBiologics during the 2nd quarter worth $37,000. Finally, Marshall Wace LLP bought a new position in shares of FibroBiologics during the 2nd quarter worth $49,000.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.